IN2012DN02073A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02073A
IN2012DN02073A IN2073DEN2012A IN2012DN02073A IN 2012DN02073 A IN2012DN02073 A IN 2012DN02073A IN 2073DEN2012 A IN2073DEN2012 A IN 2073DEN2012A IN 2012DN02073 A IN2012DN02073 A IN 2012DN02073A
Authority
IN
India
Prior art keywords
hcg
including recombinant
preparations including
preparations
recombinant hcg
Prior art date
Application number
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of IN2012DN02073A publication Critical patent/IN2012DN02073A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Preparations including recombinant HCG (r HCG).
IN2073DEN2012 2009-10-05 2010-10-04 IN2012DN02073A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05
PCT/GB2010/001854 WO2011042688A1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg

Publications (1)

Publication Number Publication Date
IN2012DN02073A true IN2012DN02073A (en) 2015-08-21

Family

ID=41471027

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2073DEN2012 IN2012DN02073A (en) 2009-10-05 2010-10-04

Country Status (25)

Country Link
US (5) US8975226B2 (en)
EP (2) EP3611185B1 (en)
JP (6) JP6176924B2 (en)
KR (7) KR20230012104A (en)
CN (1) CN107050434B (en)
AR (2) AR079876A1 (en)
AU (1) AU2010304922B2 (en)
BR (1) BR112012007990A2 (en)
CA (1) CA2776790A1 (en)
DK (1) DK2486051T3 (en)
ES (2) ES2798258T3 (en)
HR (1) HRP20200941T1 (en)
HU (1) HUE050793T2 (en)
IL (3) IL218548A (en)
IN (1) IN2012DN02073A (en)
JO (1) JOP20200039A1 (en)
LT (1) LT2486051T (en)
MX (1) MX2012003951A (en)
PL (1) PL2486051T3 (en)
PT (1) PT2486051T (en)
RS (1) RS60413B1 (en)
RU (2) RU2588650C2 (en)
SI (1) SI2486051T1 (en)
TW (2) TWI532495B (en)
WO (1) WO2011042688A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (en) * 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
TWI532495B (en) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) * 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (en) * 2011-08-08 2017-03-15 Ferring Bv Complex for controlled stimulation of the ovary
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2014092079A1 (en) 2012-12-10 2014-06-19 生化学工業株式会社 Novel recombinant factor c and method for producing same, and method for measuring endotoxin
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
LT3286209T (en) * 2015-04-24 2021-02-25 Ferring Bv Method of production of gonadotrophin
WO2016207353A1 (en) * 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
RS66871B1 (en) * 2018-04-30 2025-06-30 Ferring Bv Composition for controlled ovarian stimulation
US20210244821A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
CN116199742B (en) * 2022-07-06 2025-01-24 华兰基因工程有限公司 A method for preparing recombinant human chorionic gonadotropin Fc fusion protein

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (en) 1987-01-30 1988-07-31 Nordisk Gentofte PROCEDURE FOR TREATING INFERTILITY AND METHOD FOR USING THE PROCEDURE
IT1206302B (en) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca URINARY FOLLICLE-STIMULATING HORMONE
WO1996029095A1 (en) * 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
SI0996629T1 (en) 1997-06-25 2006-12-31 Applied Research Systems Disulfide crosslinked glycoprotein hormone analogs, their preparation and use
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
PT1176976E (en) 1999-05-07 2006-11-30 Applied Research Systems Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
IL151308A0 (en) * 2000-02-22 2003-04-10 Applied Research Systems PURIFICATION OF hCG AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EA009330B1 (en) 2001-09-12 2007-12-28 Апплайд Резеч Системз Арс Холдинг Н.В. Method encouraging implantation rates and/or decreased miscarriage rates and kit therefor
ES2261740T3 (en) * 2001-10-22 2006-11-16 Applied Research Systems Ars Holding N.V. COMPOSITIONS OF FSH WITH HIGH DEGREE OF SIGNALING AND ITS USE FOR THE PREPARATION OF MEDICINES.
CA2756610C (en) * 2001-10-29 2015-08-25 Crucell Holland B.V. Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
CN1374525A (en) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 Antibody chip, its preparation technology and detection method
MXPA05010373A (en) 2003-04-01 2005-12-05 Applied Research Systems Inhibitors of phosphodiesterases in infertility.
EP2055189A1 (en) * 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (en) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 Paper processing agent and paper
ES2425475T3 (en) * 2003-08-18 2013-10-15 Glycotope Gmbh NM-F9 (DSM ACC2606) and NM-D4 (DSM ACC2605) tumor cell lines, uses thereof
DE602005022675D1 (en) * 2004-02-04 2010-09-16 Centre Nat Rech Scient METHOD FOR IDENTIFYING GLYCOPE-SPECIFIC ANTIBODIES
EP1725673A1 (en) * 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
JP2009504985A (en) * 2005-08-15 2009-02-05 シーメンス ヴィディーオー オートモーティヴ コーポレイション Hydrocarbon metering valve to diesel vehicle exhaust
RU2309411C2 (en) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Method for selecting female patients with the syndrome of "empty" follicles for carrying out ecf and et program with donor oocytes
KR100809945B1 (en) * 2006-02-01 2008-03-05 대한민국 Evaluation method of human risk by change of normal flora in human intestine with DNA chip and normal flora in human intestine
ES2516694T3 (en) * 2006-07-21 2014-10-31 Ratiopharm Gmbh Glycosylation of peptides through glycosylation sequences with O-binding
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
TWI488640B (en) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
TWI532495B (en) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
US9757469B2 (en) * 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
JO3092B1 (en) * 2011-08-08 2017-03-15 Ferring Bv Complex for controlled stimulation of the ovary

Also Published As

Publication number Publication date
JP6310440B2 (en) 2018-04-11
US20200247863A1 (en) 2020-08-06
US20180030107A1 (en) 2018-02-01
KR20230012104A (en) 2023-01-25
JP2020000246A (en) 2020-01-09
KR102213154B1 (en) 2021-02-05
RU2016118236A3 (en) 2019-09-18
CA2776790A1 (en) 2011-04-14
HRP20200941T1 (en) 2020-09-18
KR20190067256A (en) 2019-06-14
JP7292153B2 (en) 2023-06-16
KR101987982B1 (en) 2019-06-11
ES2798258T3 (en) 2020-12-10
KR20190028823A (en) 2019-03-19
TW201113030A (en) 2011-04-16
IL267556A (en) 2019-08-29
JP2013506708A (en) 2013-02-28
US8975226B2 (en) 2015-03-10
IL218548A (en) 2017-03-30
AR079876A1 (en) 2012-02-29
PT2486051T (en) 2020-06-17
JP2018076296A (en) 2018-05-17
JP7196244B2 (en) 2022-12-26
ES3036152T3 (en) 2025-09-15
AU2010304922B2 (en) 2014-11-06
IL218548A0 (en) 2012-05-31
HUE050793T2 (en) 2021-01-28
WO2011042688A1 (en) 2011-04-14
US20220340634A1 (en) 2022-10-27
JP6580104B2 (en) 2019-09-25
EP3611185A1 (en) 2020-02-19
KR20170133531A (en) 2017-12-05
SI2486051T1 (en) 2020-08-31
KR20210141771A (en) 2021-11-23
US20140249082A1 (en) 2014-09-04
CN107050434B (en) 2021-07-27
JP2016074680A (en) 2016-05-12
US9676835B2 (en) 2017-06-13
US10526390B2 (en) 2020-01-07
RS60413B1 (en) 2020-07-31
BR112012007990A2 (en) 2017-07-25
JP2021176867A (en) 2021-11-11
US12234272B2 (en) 2025-02-25
KR101804479B1 (en) 2017-12-05
US11292824B2 (en) 2022-04-05
JP6176924B2 (en) 2017-08-09
TW201632198A (en) 2016-09-16
KR20120094909A (en) 2012-08-27
TWI604850B (en) 2017-11-11
PL2486051T3 (en) 2020-09-07
EP2486051A1 (en) 2012-08-15
EP3611185B1 (en) 2025-04-30
RU2724528C2 (en) 2020-06-23
RU2588650C2 (en) 2016-07-10
KR20210014767A (en) 2021-02-09
CN102549011A (en) 2012-07-04
RU2016118236A (en) 2018-10-29
RU2012112907A (en) 2013-11-10
IL250733B (en) 2019-07-31
US20130023476A1 (en) 2013-01-24
CN107050434A (en) 2017-08-18
JP2023075144A (en) 2023-05-30
MX2012003951A (en) 2012-05-29
AU2010304922A1 (en) 2012-03-29
AR125991A2 (en) 2023-08-30
LT2486051T (en) 2020-07-10
IL250733A0 (en) 2017-04-30
KR102489143B1 (en) 2023-01-13
EP2486051B1 (en) 2020-03-25
DK2486051T3 (en) 2020-06-22
JOP20200039A1 (en) 2022-10-30
TWI532495B (en) 2016-05-11

Similar Documents

Publication Publication Date Title
IN2012DN02073A (en)
EP4302783A3 (en) Modified relaxin polypeptides and their uses
IN2011KN03851A (en)
IN2012DN06714A (en)
AU334234S (en) Clamp for fence panels
IN2012DN04748A (en)
JO3755B1 (en) Testosterone formulations
MY168248A (en) Next-instruction-type field
MX349301B (en) Modified bovine somatotropin polypeptides and their uses.
MX2012006980A (en) Modified porcine somatotropin polypeptides and their uses.
AU2011347268A8 (en) Recombinant Mycobacterium as a vaccine
IN2011KN03928A (en)
IN2012DN04412A (en)
JO3497B1 (en) Pharmaceutical preparation comprising recombinant hcg
GB2491544A (en) Perpetum mobile
IN2012DN04805A (en)
UA42262U (en) 3-METHYL-7-β-HYDROXY-γ-(N-CHLOROPHENOXY)PROPYL-8-METHYLTHIOXANTINE EXHIBITING DIURETIC ACTION
AU313101S (en) Glass balustrading clamp - Frameless
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
CL2009001949S1 (en) ATM.
AU333244S (en) Control panel
AU325379S (en) Scarves
UA34276U (en) 7-β-HYDROXYETHYL-3-METHYL-8-N-PYRROLIDINOXANTHINE HAVING DIURETIC ACTION
CL2009001548S1 (en) Armchair.
CL2009001549S1 (en) Armchair.